Details for Patent: 12,208,102
✉ Email this page to a colleague
Which drugs does patent 12,208,102 protect, and when does it expire?
Patent 12,208,102 protects PLUVICTO and is included in one NDA.
This patent has twenty-one patent family members in sixteen countries.
Summary for Patent: 12,208,102
| Title: | Methods of treating cancer |
| Abstract: | The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating PSMA expressing cancers with a compound of the formula 1. The invention described herein also relates to methods of treating PSMA-expressing cancers with a compound of the formula 1 inpatients where stable disease results after treatment with the compound of the formula 1. |
| Inventor(s): | Alison A. Armour |
| Assignee: | Endocyte Inc |
| Application Number: | US17/047,778 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 12,208,102
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | PLUVICTO | lutetium lu-177 vipivotide tetraxetan | SOLUTION;INTRAVENOUS | 215833-001 | Mar 23, 2022 | RX | Yes | Yes | 12,208,102 | ⤷ Start Trial | FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,208,102
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 114794 | ⤷ Start Trial | |||
| Australia | 2019255692 | ⤷ Start Trial | |||
| Australia | 2025200944 | ⤷ Start Trial | |||
| Brazil | 112020020961 | ⤷ Start Trial | |||
| Canada | 3097381 | ⤷ Start Trial | |||
| Chile | 2020002637 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
